Protalix BioTherapeutics PLX Stock
Protalix BioTherapeutics Price Chart
Protalix BioTherapeutics PLX Financial and Trading Overview
| Protalix BioTherapeutics stock price | 1.96 USD |
| Previous Close | 2.11 USD |
| Open | 2.1 USD |
| Bid | 2.07 USD x 250000 |
| Ask | 2.17 USD x 680000 |
| Day's Range | 2.05 - 2.12 USD |
| 52 Week Range | 1.32 - 3.19 USD |
| Volume | 536.41K USD |
| Avg. Volume | 888.82K USD |
| Market Cap | 165.98M USD |
| Beta (5Y Monthly) | -0.009 |
| PE Ratio (TTM) | 10.842105 |
| EPS (TTM) | 0.19 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11 USD |
PLX Valuation Measures
| Enterprise Value | 123.38M USD |
| Trailing P/E | 10.842105 |
| Forward P/E | 3.3225806 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2.1730216 |
| Price/Book (mrq) | 2.4700239 |
| Enterprise Value/Revenue | 1.615 |
| Enterprise Value/EBITDA | 5.788 |
Trading Information
Protalix BioTherapeutics Stock Price History
| Beta (5Y Monthly) | -0.009 |
| 52-Week Change | 33.54% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 3.19 USD |
| 52 Week Low | 1.32 USD |
| 50-Day Moving Average | 2.13 USD |
| 200-Day Moving Average | 2.14 USD |
PLX Share Statistics
| Avg. Volume (3 month) | 888.82K USD |
| Avg. Daily Volume (10-Days) | 828.74K USD |
| Shares Outstanding | 80.57M |
| Float | 72.73M |
| Short Ratio | 5.29 |
| % Held by Insiders | 3.87% |
| % Held by Institutions | 21.30% |
| Shares Short | 4.18M |
| Short % of Float | 5.40% |
| Short % of Shares Outstanding | 5.19% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 20.07% |
| Operating Margin (ttm) | 62.65% |
| Gross Margin | 45.23% |
| EBITDA Margin | 27.90% |
Management Effectiveness
| Return on Assets (ttm) | 14.03% |
| Return on Equity (ttm) | 27.27% |
Income Statement
| Revenue (ttm) | 76.38M USD |
| Revenue Per Share (ttm) | 0.96 USD |
| Quarterly Revenue Growth (yoy) | 233.70% |
| Gross Profit (ttm) | 34.55M USD |
| EBITDA | 21.31M USD |
| Net Income Avi to Common (ttm) | 15.33M USD |
| Diluted EPS (ttm) | 0.19 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 51.08M USD |
| Total Cash Per Share (mrq) | 0.63 USD |
| Total Debt (mrq) | 8.48M USD |
| Total Debt/Equity (mrq) | 12.62 USD |
| Current Ratio (mrq) | 3.153 |
| Book Value Per Share (mrq) | 0.834 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 15.09M USD |
| Levered Free Cash Flow (ttm) | 6.78M USD |
Profile of Protalix BioTherapeutics
| Country | United States |
| State | NJ |
| City | Hackensack |
| Address | 2 University Plaza |
| ZIP | 07601 |
| Phone | 201 696 9345 |
| Website | https://www.protalix.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 226 |
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Q&A For Protalix BioTherapeutics Stock
What is a current PLX stock price?
Protalix BioTherapeutics PLX stock price today per share is 1.96 USD.
How to purchase Protalix BioTherapeutics stock?
You can buy PLX shares on the NYSE American exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Protalix BioTherapeutics?
The stock symbol or ticker of Protalix BioTherapeutics is PLX.
Which industry does the Protalix BioTherapeutics company belong to?
The Protalix BioTherapeutics industry is Biotechnology.
How many shares does Protalix BioTherapeutics have in circulation?
The max supply of Protalix BioTherapeutics shares is 80.57M.
What is Protalix BioTherapeutics Price to Earnings Ratio (PE Ratio)?
Protalix BioTherapeutics PE Ratio is 10.31579000 now.
What was Protalix BioTherapeutics earnings per share over the trailing 12 months (TTM)?
Protalix BioTherapeutics EPS is 0.19 USD over the trailing 12 months.
Which sector does the Protalix BioTherapeutics company belong to?
The Protalix BioTherapeutics sector is Healthcare.
Protalix BioTherapeutics PLX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NYSE American Composite Index XAX | 8750.58 USD — |
-0.14
|
— — | 8749.41 USD — | 8844.17 USD — | — - | — — |
- {{ link.label }} {{link}}